For the year ending 2025-12-31, PBYI made $228,371K in revenue. $31,111K in net income. Net profit margin of 13.62%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenue | 228,371 | 230,468 | ||
| Cost of sales | 58,157 | 64,404 | ||
| Selling, general and administrative | 70,847 | 80,163 | ||
| Research and development | 62,068 | 54,935 | ||
| Total operating costs and expenses | 191,072 | 199,502 | ||
| Income from operations | 37,299 | 30,966 | ||
| Interest income | 4,078 | 4,724 | ||
| Interest expense | 6,622 | 12,452 | ||
| Other income | 1,027 | 862 | ||
| Total other expenses, net | -1,517 | -6,866 | ||
| Income before income taxes | 35,782 | 24,100 | ||
| Current income tax (expense) | 1,426 | 897 | ||
| Deferred income tax (expense) benefit | 3,245 | -7,075 | ||
| Net income | 31,111 | 30,278 | ||
| Basic EPS | 0.62 | 0.62 | ||
| Diluted EPS | 0.61 | 0.62 | ||
| Basic Average Shares | 50,011,485 | 48,648,701 | ||
| Diluted Average Shares | 50,653,283 | 49,100,433 | ||
PUMA BIOTECHNOLOGY, INC. (PBYI)
PUMA BIOTECHNOLOGY, INC. (PBYI)